Symbols / SCNX
SCNX Chart
About
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Pharmaceutical Retailers | Market Cap | 15.62M |
| Enterprise Value | 17.31M | Income | -20.19M | Sales | 653.39K |
| Book/sh | 3.57 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | 0.51 | Forward P/E | -0.53 | PEG | — |
| P/S | 23.90 | P/B | 0.11 | P/C | — |
| EV/EBITDA | -1.00 | EV/Sales | 26.50 | Quick Ratio | 0.13 |
| Current Ratio | 0.19 | Debt/Eq | 3.09 | LT Debt/Eq | — |
| EPS (ttm) | 0.75 | EPS next Y | -0.72 | EPS Growth | — |
| Revenue Growth | 8.10% | Earnings | — | ROA | -10.87% |
| ROE | -24.07% | ROIC | — | Gross Margin | 88.48% |
| Oper. Margin | -7.39% | Profit Margin | 0.00% | Shs Outstand | 40.63M |
| Shs Float | 33.79M | Short Float | 7.29% | Short Ratio | 1.75 |
| Short Interest | — | 52W High | 3.61 | 52W Low | 0.38 |
| Beta | — | Avg Volume | 1.27M | Volume | 253.03K |
| Target Price | $1.50 | Recom | None | Prev Close | $0.37 |
| Price | $0.38 | Change | 3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$1.50
Mean price target
2. Current target
$0.38
Latest analyst target
3. DCF / Fair value
$0.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.38
Low
$1.50
High
$1.50
Mean
$1.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Maxim Group | — → Buy | $2 |
- Maxim Group Initiates Coverage on Scienture Holdings (SCNX) with a 'Buy' Rating | SCNX Stock News - GuruFocus ue, 24 Feb 2026 18
- Scienture (NASDAQ: SCNX) begins Arbli sales; $256M losartan market, 2,500 institutions - Stock Titan hu, 23 Oct 2025 07
- Scienture stock plummets after announcing $3.9 million registered offering - Investing.com hu, 14 Aug 2025 07
- Why Did Scienture Stock (SCNX) Soar 45% Today? - TipRanks hu, 23 Oct 2025 07
- EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives - Yahoo Finance ue, 04 Nov 2025 08
- SCNX Shares Soar After Milestone Achievement - StocksToTrade ue, 04 Nov 2025 08
- Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli - Investorideas.com hu, 23 Oct 2025 07
- SCNX Stock Climbs Amid Strategic Partnership Talks - timothysykes.com Sun, 26 Oct 2025 07
- SCNX Explodes Higher on Breakthrough Launch of Game-Changing Liquid Blood Pressure Treatment! - RagingBull hu, 16 Oct 2025 07
- Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next? - TechStock² Fri, 24 Oct 2025 07
- Scienture Secures $3.9 Mln Through Registered Direct Stock Offering - Nasdaq hu, 14 Aug 2025 07
- Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum? - Benzinga hu, 23 Oct 2025 07
- Scienture stock soars as first FDA-approved losartan oral suspension hits market - Investing.com hu, 23 Oct 2025 07
- EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction - Yahoo Finance hu, 13 Nov 2025 08
- First FDA-approved liquid losartan hits distribution centers as Scienture targets $276M market - Stock Titan Wed, 13 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -81.89K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.03 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.51M | -3.34M | -1.83M | -3.55M |
| TotalUnusualItems | -2.88M | -2.95M | -47.51K | -1.60M |
| TotalUnusualItemsExcludingGoodwill | -2.88M | -2.95M | -47.51K | -1.60M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.24M | -8.48M | -1.97M | -5.32M |
| ReconciledDepreciation | 53.36K | 1.05M | 194.70K | 138.91K |
| ReconciledCostOfRevenue | 130.64K | 1.31M | 4.73M | 5.14M |
| EBITDA | -17.39M | -6.29M | -1.87M | -5.15M |
| EBIT | -17.44M | -7.34M | -2.07M | -5.29M |
| NetInterestIncome | -1.20M | -1.14M | -315.22K | -23.59K |
| InterestExpense | 1.34M | 1.14M | 336.21K | 23.59K |
| InterestIncome | 135.34K | 4.20K | 20.99K | 0.00 |
| NormalizedIncome | -15.45M | -5.54M | -1.92M | -3.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 9.07M | -17.84M | -3.47M | -5.32M |
| TotalExpenses | 14.84M | 5.76M | 12.29M | 13.58M |
| TotalOperatingIncomeAsReported | -14.70M | -4.40M | -2.92M | -5.29M |
| DilutedAverageShares | 3.65M | 2.38M | 564.86K | 542.45K |
| BasicAverageShares | 3.38M | 764.06K | 564.86K | 542.45K |
| DilutedEPS | 2.48 | -23.35 | -6.15 | -9.75 |
| BasicEPS | 2.69 | -23.35 | -6.15 | -9.75 |
| DilutedNIAvailtoComStockholders | 9.07M | -17.84M | -3.47M | -5.32M |
| NetIncomeCommonStockholders | 9.07M | -17.84M | -3.47M | -5.32M |
| NetIncome | 9.07M | -17.84M | -3.47M | -5.32M |
| MinorityInterests | 0.00 | 437.77K | 0.00 | |
| NetIncomeIncludingNoncontrollingInterests | 9.07M | -17.84M | -3.91M | -5.32M |
| NetIncomeDiscontinuousOperations | 27.31M | -9.36M | -1.51M | |
| NetIncomeContinuousOperations | -18.24M | -8.48M | -2.40M | -5.32M |
| TaxProvision | -534.40K | 0.00 | ||
| PretaxIncome | -18.78M | -8.48M | -2.40M | -5.32M |
| OtherIncomeExpense | -2.88M | -2.95M | -47.51K | -1.60M |
| OtherNonOperatingIncomeExpenses | 14.54K | -1.23M | ||
| SpecialIncomeCharges | -2.87M | -2.80M | -873.05K | -1.60M |
| GainOnSaleOfPPE | -374.97K | -2.80M | 2.20K | 0.00 |
| WriteOff | 2.50M | 0.00 | 875.25K | 1.60M |
| ImpairmentOfCapitalAssets | 5.13M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | -2.60K | -148.42K | 825.54K | |
| NetNonOperatingInterestIncomeExpense | -1.20M | -1.14M | -315.22K | -23.59K |
| InterestExpenseNonOperating | 1.34M | 1.14M | 336.21K | 23.59K |
| InterestIncomeNonOperating | 135.34K | 4.20K | 20.99K | 0.00 |
| OperatingIncome | -14.70M | -4.40M | -2.04M | -3.69M |
| OperatingExpense | 14.71M | 4.45M | 7.56M | 8.44M |
| OtherOperatingExpenses | 416.31K | 100.28K | 993.18K | 899.71K |
| ResearchAndDevelopment | 2.24M | 0.00 | 993.18K | 899.71K |
| SellingGeneralAndAdministration | 12.05M | 4.35M | 6.57M | 7.54M |
| GeneralAndAdministrativeExpense | 12.05M | 4.35M | 6.57M | 7.54M |
| OtherGandA | 9.94M | 3.72M | 2.99M | 3.69M |
| SalariesAndWages | 2.11M | 626.55K | 3.58M | 3.85M |
| GrossProfit | 6.00K | 49.03K | 5.52M | 4.75M |
| CostOfRevenue | 130.64K | 1.31M | 4.73M | 5.14M |
| TotalRevenue | 136.64K | 1.36M | 10.25M | 9.89M |
| OperatingRevenue | 136.64K | 1.36M | 10.25M | 9.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.75M | 905.01K | 626.25K | 544.43K |
| ShareIssued | 8.75M | 905.01K | 626.25K | 544.43K |
| NetDebt | 3.00M | 6.40M | ||
| TotalDebt | 3.53M | 209.50K | 1.58M | 1.25M |
| TangibleBookValue | -18.70M | 542.35K | 763.14K | 3.77M |
| InvestedCapital | 82.38M | 542.35K | 1.26M | 3.77M |
| WorkingCapital | -1.60M | -8.80M | -53.67K | 3.45M |
| NetTangibleAssets | -18.70M | 542.35K | 763.14K | 3.77M |
| CapitalLeaseObligations | 219.80K | 209.50K | 1.08M | 1.25M |
| CommonStockEquity | 79.07M | 542.35K | 763.14K | 3.77M |
| TotalCapitalization | 79.68M | 542.35K | 1.10M | 3.77M |
| TotalEquityGrossMinorityInterest | 79.07M | 542.35K | 342.87K | 3.77M |
| MinorityInterest | 0.00 | -420.27K | 0.00 | |
| StockholdersEquity | 79.07M | 542.35K | 763.14K | 3.77M |
| RetainedEarnings | -39.04M | -33.25M | -19.72M | -16.25M |
| AdditionalPaidInCapital | 118.11M | 33.79M | 20.48M | 20.02M |
| CapitalStock | 87.00 | 9.00 | 6.00 | 82.00 |
| CommonStock | 87.00 | 9.00 | 6.00 | 82.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 25.78M | 11.99M | 3.37M | 2.00M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 17.87M | 434.20K | 1.22M | 1.07M |
| OtherNonCurrentLiabilities | 1.28M | |||
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 257.30K | ||
| DerivativeProductLiabilities | 2.30M | 0.00 | ||
| NonCurrentDeferredLiabilities | 13.52M | |||
| NonCurrentDeferredTaxesLiabilities | 13.52M | |||
| LongTermDebtAndCapitalLeaseObligation | 768.74K | 176.91K | 1.22M | 1.07M |
| LongTermCapitalLeaseObligation | 156.47K | 176.91K | 887.03K | 1.07M |
| LongTermDebt | 612.27K | 25.00K | 333.33K | |
| CurrentLiabilities | 7.91M | 11.56M | 2.15M | 926.03K |
| OtherCurrentLiabilities | 930.72K | 9.90M | 916.52K | |
| CurrentDeferredLiabilities | 0.00 | 5.13K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 5.13K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 2.76M | 32.59K | 363.54K | 178.56K |
| CurrentCapitalLeaseObligation | 63.33K | 32.59K | 196.87K | 178.56K |
| CurrentDebt | 2.70M | 6.53M | 166.67K | |
| OtherCurrentBorrowings | 2.70M | 6.53M | 166.67K | |
| CurrentNotesPayable | 166.67K | 0.00 | ||
| PayablesAndAccruedExpenses | 4.21M | 1.62M | 861.60K | 747.47K |
| CurrentAccruedExpenses | 1.31M | 160.21K | 271.23K | 270.44K |
| Payables | 2.90M | 1.46M | 590.37K | 477.03K |
| OtherPayable | 420.31K | 62.39K | ||
| AccountsPayable | 2.90M | 1.46M | 527.98K | 477.03K |
| TotalAssets | 104.85M | 12.53M | 3.71M | 5.77M |
| TotalNonCurrentAssets | 98.55M | 9.78M | 1.62M | 1.39M |
| OtherNonCurrentAssets | 9.57M | 450.85K | ||
| NonCurrentPrepaidAssets | 22.04K | 10.53K | 49.03K | 60.14K |
| NonCurrentDeferredAssets | 534.40K | |||
| NonCurrentDeferredTaxesAssets | 534.40K | |||
| GoodwillAndOtherIntangibleAssets | 97.77M | 0.00 | 0.00 | 0.00 |
| OtherIntangibleAssets | 76.40M | 8.96M | ||
| Goodwill | 21.37M | 0.00 | ||
| NetPPE | 218.93K | 198.72K | 1.12M | 1.33M |
| GrossPPE | 218.93K | 198.72K | 1.12M | 1.33M |
| OtherProperties | 218.93K | 198.72K | 1.12M | 1.33M |
| CurrentAssets | 6.31M | 2.75M | 2.09M | 4.37M |
| AssetsHeldForSaleCurrent | 8.14K | 176.35K | 198.32K | |
| CurrentDeferredAssets | 534.80K | 0.00 | ||
| PrepaidAssets | 4.56K | 50.72K | 104.46K | 216.41K |
| Inventory | 0.00 | 968.00 | 65.52K | 56.28K |
| FinishedGoods | 0.00 | 968.00 | 0.00 | |
| RawMaterials | 0.00 | 65.52K | ||
| Receivables | 5.45M | 2.52M | 629.92K | 978.97K |
| OtherReceivables | 4.14M | 1.22M | ||
| NotesReceivable | 1.30M | 1.30M | 0.00 | |
| AccountsReceivable | 11.11K | 0.00 | 629.92K | 978.97K |
| AllowanceForDoubtfulAccountsReceivable | -32.07K | -98.84K | -615.66K | |
| GrossAccountsReceivable | 853.88K | 728.76K | 1.59M | |
| CashCashEquivalentsAndShortTermInvestments | 308.10K | 314.00 | 1.09M | 3.12M |
| CashAndCashEquivalents | 308.10K | 314.00 | 1.09M | 3.12M |
| CashFinancial | 308.10K | 314.00 | 1.09M | 3.12M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.27M | -2.23M | -1.56M | -2.59M |
| RepaymentOfDebt | 0.00 | -150.00K | 0.00 | -225.00K |
| IssuanceOfDebt | 3.10M | 400.00K | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 130.92K | 0.00 | |
| CapitalExpenditure | -450.85K | -22.60K | ||
| InterestPaidSupplementalData | 0.00 | 733.69K | 336.21K | 28.34K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 308.10K | 314.00 | 1.09M | 3.12M |
| BeginningCashPosition | 314.00 | 1.09M | 3.12M | 5.92M |
| ChangesInCash | 307.78K | -1.09M | -2.03M | -2.80M |
| FinancingCashFlow | -12.98M | 1.41M | -35.17K | -208.18K |
| CashFromDiscontinuedFinancingActivities | -5.00K | -500.00K | -275.00K | |
| CashFlowFromContinuingFinancingActivities | -12.97M | 1.91M | 239.83K | -208.18K |
| NetOtherFinancingCharges | -1.25M | 1.65M | 108.04K | |
| ProceedsFromStockOptionExercised | 26.41K | 1.62K | 875.00 | 16.82K |
| CashDividendsPaid | -14.86M | 0.00 | ||
| CommonStockDividendPaid | -14.86M | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 130.92K | 0.00 | |
| CommonStockIssuance | 0.00 | 130.92K | 0.00 | |
| NetIssuancePaymentsOfDebt | 3.10M | 250.00K | 0.00 | -225.00K |
| NetShortTermDebtIssuance | -225.00K | |||
| ShortTermDebtPayments | -225.00K | |||
| NetLongTermDebtIssuance | 3.10M | 250.00K | 0.00 | -225.00K |
| LongTermDebtPayments | 0.00 | -150.00K | 0.00 | -225.00K |
| LongTermDebtIssuance | 3.10M | 400.00K | 0.00 | |
| InvestingCashFlow | 27.55M | -275.72K | -427.85K | -22.60K |
| CashFromDiscontinuedInvestingActivities | 29.93M | 68.74K | -428.59K | |
| CashFlowFromContinuingInvestingActivities | -2.38M | -344.45K | 749.00 | -22.60K |
| NetOtherInvestingChanges | -12.00K | |||
| NetInvestmentPurchaseAndSale | -2.50M | 0.00 | ||
| PurchaseOfInvestment | -2.50M | 0.00 | ||
| NetBusinessPurchaseAndSale | 132.98K | -344.45K | 0.00 | |
| SaleOfBusiness | 132.98K | 0.00 | ||
| PurchaseOfBusiness | 0.00 | -344.45K | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | 749.00 | -22.60K | |
| SaleOfPPE | 0.00 | 749.00 | 0.00 | |
| PurchaseOfPPE | 0.00 | -22.60K | ||
| CapitalExpenditureReported | 0.00 | 0.00 | 0.00 | |
| OperatingCashFlow | -14.27M | -2.23M | -1.56M | -2.57M |
| CashFromDiscontinuedOperatingActivities | -979.08K | -5.87M | -1.37M | |
| CashFlowFromContinuingOperatingActivities | -13.29M | 3.65M | -199.02K | -2.57M |
| ChangeInWorkingCapital | -2.60M | 5.51M | 257.58K | 1.08M |
| ChangeInOtherWorkingCapital | -10.00K | |||
| ChangeInOtherCurrentLiabilities | -113.98K | -225.68K | 491.43K | -131.15K |
| ChangeInOtherCurrentAssets | 306.53K | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 403.96K | 2.02M | -11.86K | 206.38K |
| ChangeInAccruedExpense | -44.62K | 58.69K | -211.69K | -13.82K |
| ChangeInPayable | 448.57K | 1.96M | 199.83K | 220.20K |
| ChangeInAccountPayable | 448.57K | 1.61M | 199.83K | 220.20K |
| ChangeInPrepaidAssets | 34.66K | 38.37K | 335.07K | -103.67K |
| ChangeInInventory | 968.00 | 4.23M | -51.74K | 825.13K |
| ChangeInReceivables | -2.93M | -548.71K | -505.32K | 298.09K |
| ChangesInAccountReceivables | -11.11K | -293.78K | 369.93K | -789.59K |
| OtherNonCashItems | 5.51M | 257.77K | 254.11K | 181.16K |
| StockBasedCompensation | 257.77K | 254.11K | 181.16K | |
| AssetImpairmentCharge | 2.50M | 5.13M | 1.42M | 1.14M |
| DepreciationAmortizationDepletion | 53.36K | 1.05M | 194.70K | 138.91K |
| DepreciationAndAmortization | 53.36K | 1.05M | 194.70K | 138.91K |
| AmortizationCashFlow | 0.00 | 814.79K | 0.00 | |
| AmortizationOfIntangibles | 0.00 | 814.79K | 0.00 | |
| Depreciation | 53.36K | 235.04K | 194.70K | 138.91K |
| OperatingGainsLosses | 28.18K | 178.16K | 76.96K | 208.91K |
| GainLossOnInvestmentSecurities | 28.18K | 178.16K | 79.16K | 208.91K |
| NetIncomeFromContinuingOperations | -18.78M | -8.48M | -2.40M | -5.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SCNX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|